论文部分内容阅读
AIM To evaluate the efficacy and safety of the TECA-Ibloartificial liver support system(BALSS)in treatingcanines with acute liver failure(ALF).METHODS Ten canines with ALF induced by 80% liverresection received BALSS treatment(BALSS group).Blood was perfused through a hollow fiber tube containing1×10~(10) porcine hepatocytes.Four canines with ALF weretreated with BALSS without porcine hepatocytes(controlgroup),and five canines with ALF received drugtreatment(drug group).Each treatment lasted 6 hours.RESULTS BALSS treatment yielded beneficial effects forpartial liver resection-induced ALF canines with survivaland decreased plasma ammonia,ALT,AST and BIL.Therewas an obvious decrease in PT level and increase in PAlevel,and there were no changes in the count oflymphocytes,immunoglobulins(IgA,IgG and IgM)andcomplement(C3 and CA)levels after BALSS treatment.Incontrast,for the canines with ALF in non-hepatocyteBALSS group(control group)and drug group,there wereno significant changes in ammonia,ALT,AST,BIL,PTand PA levels.ALF canines in BALSS group,controlgroup and drug group lived respectively an average timeof 108.0h±12.0h,24.0h±6.0h and 20.4h±6.4h,andthree canines with ALF survived in BALSS group.CONCLUSION TECA-I BALSS is efficacious and safe forALF canines induced by parcial liver resection.
AIM To evaluate the efficacy and safety of the TECA-Ibloartificial liver support system (BALSS) in treatingcanines with acute liver failure (ALF) .METHODS Ten canines with ALF induced by BALSS treatment (80% liver transplant) (BALSS group) .Blood was perfused through A hollow fiber tube containing 1 × 10 10 porcine hepatocytes. Four canines with ALF were treated with BALSS without porcine hepatocytes (controlgroup), and five canines with ALF received drug treatment (drug group) .Each treatment lasted 6 hours.RESULTS BALSS treatment yielded beneficial effects forpartial liver resection-induced ALF canines with survivaland decreased plasma ammonia, ALT, AST and BIL.Therewas an obvious decrease in PT level and increase in PAlevel, and there were no changes in the count of lymphocytes, immunoglobulins (IgA, IgG and IgM ) and complex (C3 and CA) levels after BALSS treatment. contratrast, for the canines with ALF in non-hepatocyteBALSS group (control group) and drug group, there wereno significant changes in ammoniac ia, ALT, AST, BIL, PTand PA levels. ALF canines in BALSS group, controlgroup and drug group lived respectively an average time of 108.0h ± 12.0h, 24.0h ± 6.0h and 20.4h ± 6.4h, and canines with ALF survived in BALSS group. CONCLUSION TECA-I BALSS is efficacious and safe for ALF canines induced by parcial liver resection.